Bhanji Muna 4

What Happened Muna Bhanji, a director of Cytokinetics, received equity awards on 2026-05-27 totaling 7,152 shares. The filing shows a direct award of 2,851 common shares at $0.00 and a derivative award of 4,301 shares at $0.00 (reported as acquisitions, total reported value $0). These were awards/grants (compensation) rather than open‑market purchases or sales.

Key Details

• Transaction date: 2026-05-27 (Form 4 filed 2026-05-27).
• Grants: 2,851 shares acquired directly at $0.00; 4,301 shares acquired as a derivative award at $0.00.
• Total new shares reported: 7,152.
• Shares owned after the transaction: not disclosed on this filing.
• Footnotes/plan details: none specified on the Form 4 (no 10b5-1, tax‑withholding, or sale noted).
• Timeliness: filing date matches the report date — appears to be filed timely.

Context Awards reported as $0 typically reflect compensation grants such as restricted stock or RSUs that vest over time; the derivative entry likely represents stock units or other awards that will convert to shares upon vesting. Such compensation is routine for executives and directors and does not by itself indicate a personal purchase or sale decision.